As of Apr 20
| +0.13 / +1.53%|
The 4 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 31.50, with a high estimate of 41.00 and a low estimate of 13.00. The median estimate represents a +265.43% increase from the last price of 8.62.
The current consensus among 4 polled investment analysts is to Buy stock in Repros Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.